Heat Biologics Stock News

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with

09 Jun 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Director Clinical Development and Regulatory Affairs Chri

NanOlogy initiates clinical trial in lung cancer utilizing NanoPac based on submicron technology.

DURHAM, NC / ACCESSWIRE / June 8, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,

Genprex's CEO will Present at the MoneyShow Virtual Event on June 10

SAN DIEGO, June 5, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage...

Regeneron has both added to its current growth drivers and developed an impressive pipeline that should fuel performance throughout the decade. Eylea will benef

After swinging the ax on staffers last year and gaining a new CEO a few months back, Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Phar

DURHAM, NC / ACCESSWIRE / June 4, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,